

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Easy Smart Group Holdings Limited**

### **怡俊集團控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2442)**

## **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Easy Smart Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Wang Jun (王軍) (“**Mr. Wang**”) has been appointed as an executive Director of the Company with effect from 4th August 2025.

The biographical details of Mr. Wang are set out below:

**Mr. Wang Jun (王軍)**, aged 57, is the president, a director and a controlling shareholder holding 68.39% of Yubo International Biotech Limited (“**Yubo International**”), a company listed on the United States of America OTCQB Market with stock code: YBGJ. Yubo International, through its wholly-owned subsidiaries and certain contractual arrangements with a People’s Republic of China (“**PRC**”) entity, which provides research and development and application of endometrial stem cells and is committed to building the first public endometrial stem cell repository in the world. From June 2004 to August 2009, Mr. Wang worked as general manager of Beijing Jinhai Yijia Health Technology Co., Ltd.\* (北京金海益家健康科技有限公司). From August 2009 to June 2020, Mr. Wang had been the president of Beijing Yijia Times Technology Service Co., Ltd.\* (北京益家時代科技服務有限公司). In June 2026, Mr. Wang as one of the founders set up Yubo International Biotechnology (Beijing) Group Co., Ltd.\* (羽鉑國際生物科技(北京)集團有限公司) (“**Yubo Beijing**”) in Beijing, PRC and has been its president since then. Yubo Beijing is a biotechnology company using the endometrial stem cell bank as its core technology and to develop a series of human stem cell-based products and possesses a series of light application products of stem cells under the brand name “VIVICELL”, including aerosol inhalers for repairing pulmonary fibrosis, cytokine repair agents for dry eyes, secretin for hair loss, microcapsule powder for skin repair, cell gel for repairing pelvic floor muscles in gynecology. Mr. Wang also serves as the president of Yubo Global Biotechnology (Chengdu) Co., Ltd.\* (羽鉑環球生物科技(成都)有限公司) since December 2020, the president of Yubo Refined Biotechnology (Chengdu) Co., Ltd.\* (羽鉑精製生物技術(成都)有限公司) since January 2021, a director of Xin’an Jin Biotechnology (Shenzhen) Co., Ltd.\* (新安津生物科技(深圳)有限公司) since September 2024 and the president of Bio Life Sciences Development Holdings (Shenzhen) Co., Ltd.\* (拜奧生命科學發展控股(深圳)有限公司).

Mr. Wang has entered into a service contract with the Company for an initial term of 2 years commencing from 4th August 2025, which will be renewed and extended automatically by 1 year on the expiry of such initial term, but he is subject to retirement by rotation and re-election at the annual general meeting of the Company pursuant to the articles of association of the Company and until terminated by either party giving at least 1 month's written notice of termination. Mr. Wang will receive a director's fee of HK\$20,000 per month, which is determined with reference to his duties and responsibilities and the remuneration policy of the Company.

Mr. Wang does not have any interests in the shares (the “**Shares**”), underlying Shares and debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

Save as disclosed herein, as at the date of this announcement, Mr. Wang confirmed that (i) he has not held any other directorship in other listed public company in Hong Kong or overseas during the past three years preceding the date of this announcement; (ii) he does not hold any other positions with the Company or any of its subsidiaries; (iii) he does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (each as defined under the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”)) of the Company; and (iv) there are no other matters in relation to the appointment of Mr. Wang as an executive Director that need to be brought to the attention of the shareholders of the Company and the Stock Exchange, and there is no other information required to be disclosed under Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to extend a welcome to Mr. Wang for joining the Board.

By order of the Board  
**Easy Smart Group Holdings Limited**  
**Ng Wing Woon Dave**  
*Chairman of the Board and Executive Director*

Hong Kong, 4th August 2025

*As at the date of this announcement, the Board comprises Mr. Ng Wing Woon Dave, Mr. Ng Wing Shing and Mr. Wang Jun as executive Directors; and Prof. Pong Kam Keung, Ms. Cheng Shing Yan and Mr. Lo Chi Wang as independent non-executive Directors.*

\* *For identification purposes only*